Our Company Strategy & Mission Leadership Our Board Partnering Opportunities Out-Licensing Opportunities Contact Our Pipeline Clinical Trials Disease Information Innovation Engine Akeso Partnership Overview Ivonescimab (SMT112) Overview Therapeutic Areas News Center Media Resources Press Releases Investor Center Investor Center Announcements, Financial Reports & Filings Email Alerts Share Price Data Analyst Coverage Corporate Governance Board of Directors Diversity Matrix Shareholder Meetings Summit Presentations Career Opportunities
Preservation of Gut Microbiome Following Ridinilazole versus Fidaxomicin Treatment of Clostridium difficile Infection Preservation of Gut Microbiome Following Ridinilazole versus Fidaxomicin Treatment of Clostridium difficile Infection October 9, 2017 By CKD Digital
Preservation of Gut Microbiome Following Ridinilazole versus Fidaxomicin Treatment of Clostridium difficile Infection
Preservation of Gut Microbiome Following Ridinilazole versus Fidaxomicin Treatment of Clostridium difficile Infection October 9, 2017 By CKD Digital
Website Cookies This website uses cookies: Please see our Privacy Policy to understand how we use cookies. Okay, thanks